Filing Flows › Recursion Pharmaceuticals (RXRX) › Q1 2025
Recursion Pharmaceuticals (RXRX) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 5, 2025
Recursion Pharmaceuticals (RXRX) reported revenue of $14.7M for the first quarter 2025 (Q1 2025), +7% from a year earlier and +224% from the quarter before.
Recursion Pharmaceuticals, Q1 2025: revenue $14.7M (+7% year over year), net loss $202M, operating cash flow −$132M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $14.7M | +224% | +7% |
| Operating profit | −$191M | — | — |
| Net earnings | −$202M | — | — |
| Operating cash flow | −$132M | — | — |
What changed
Revenue was $14.7M in Q1 2025, up 7% year over year and up 224% from the previous quarter.
Operating costs exceeded revenue by $191.4M, an operating margin of -1297.9%. Total costs grew 87% against revenue growth of 7%. The fastest-growing cost line was Cost of revenue (+95%). The quarter ended with a net loss of $202.5M, wider than the previous quarter's $178.9M loss.
Operating cash flow was −$132.0M. Non-cash charges added back $19.3M of depreciation and amortization and $36.1M of share-based compensation. Working capital and other items added $15.1M. Capital expenditures of $1.8M exceeded it, leaving free cash flow of −$133.8M.
Questions
What was Recursion Pharmaceuticals' revenue in the first quarter 2025?
Recursion Pharmaceuticals (RXRX) reported revenue of $14.7M for the first quarter 2025 (Q1 2025), +7% from a year earlier and +224% from the quarter before.